Optimizing treatment of desmoid tumors

Dina Lev, Dhanasekaran Kotilingam, Caimiao Wei, Matthew Ballo, Gunar K. Zagars, Peter W T Pisters, Alexander A. Lazar, Shreyaskumar R. Patel, Robert S. Benjamin, Raphael E. Pollock

Research output: Contribution to journalArticle

178 Citations (Scopus)

Abstract

Purpose: This study compared a large series of desmoid patients treated at a single institution to a previously published series from the same institution to determine if patient population characteristics, treatment approaches, and clinical outcomes had undergone change over the two study periods. Materials and Methods: Data from a prospective soft tissue tumor database was used to analyze clinical courses of 189 desmoid patients treated at The University of Texas M.D. Anderson Cancer Center (UTMDACC) from 1995 to 2005 as compared with 189 UTMDACC desmoid patients treated between 1965 and 1994. Results: A nearly three-fold increase in annualized UTMDACC desmoid referral volume with significantly higher percentages and numbers of primary desmoid tumor referrals to UTMDACC was observed in the most recent study period. Significantly increased systemic therapy use and decreased reliance on surgery alone was observed more recently. While the recent series patients had higher rates of macroscopic residual disease and equivalent rates of positive microscopic margins after definitive surgery, the estimated 5-year local recurrence rate of 20% was improved compared with the 30% rate observed in the earlier series. Conclusion: Increased awareness of the complex multidisciplinary management needed for desmoid tumor control may underlie significantly increased numbers of referrals to UTMDACC, especially primary untreated desmoids. Increased neoadjuvant treatments may be associated with improved desmoid patient outcomes. These trends should be supported, particularly if personalized molecular-based therapies are to be rapidly and effectively deployed for the benefit of those afflicted by this rare and potentially debilitating disease.

Original languageEnglish (US)
Pages (from-to)1785-1791
Number of pages7
JournalJournal of Clinical Oncology
Volume25
Issue number13
DOIs
StatePublished - May 1 2007
Externally publishedYes

Fingerprint

Aggressive Fibromatosis
Neoplasms
Referral and Consultation
Therapeutics
Neoadjuvant Therapy
Population Characteristics
Databases
Recurrence

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Lev, D., Kotilingam, D., Wei, C., Ballo, M., Zagars, G. K., Pisters, P. W. T., ... Pollock, R. E. (2007). Optimizing treatment of desmoid tumors. Journal of Clinical Oncology, 25(13), 1785-1791. https://doi.org/10.1200/JCO.2006.10.5015

Optimizing treatment of desmoid tumors. / Lev, Dina; Kotilingam, Dhanasekaran; Wei, Caimiao; Ballo, Matthew; Zagars, Gunar K.; Pisters, Peter W T; Lazar, Alexander A.; Patel, Shreyaskumar R.; Benjamin, Robert S.; Pollock, Raphael E.

In: Journal of Clinical Oncology, Vol. 25, No. 13, 01.05.2007, p. 1785-1791.

Research output: Contribution to journalArticle

Lev, D, Kotilingam, D, Wei, C, Ballo, M, Zagars, GK, Pisters, PWT, Lazar, AA, Patel, SR, Benjamin, RS & Pollock, RE 2007, 'Optimizing treatment of desmoid tumors', Journal of Clinical Oncology, vol. 25, no. 13, pp. 1785-1791. https://doi.org/10.1200/JCO.2006.10.5015
Lev D, Kotilingam D, Wei C, Ballo M, Zagars GK, Pisters PWT et al. Optimizing treatment of desmoid tumors. Journal of Clinical Oncology. 2007 May 1;25(13):1785-1791. https://doi.org/10.1200/JCO.2006.10.5015
Lev, Dina ; Kotilingam, Dhanasekaran ; Wei, Caimiao ; Ballo, Matthew ; Zagars, Gunar K. ; Pisters, Peter W T ; Lazar, Alexander A. ; Patel, Shreyaskumar R. ; Benjamin, Robert S. ; Pollock, Raphael E. / Optimizing treatment of desmoid tumors. In: Journal of Clinical Oncology. 2007 ; Vol. 25, No. 13. pp. 1785-1791.
@article{8558b5f82d184f61b0ff1bee1bd5284f,
title = "Optimizing treatment of desmoid tumors",
abstract = "Purpose: This study compared a large series of desmoid patients treated at a single institution to a previously published series from the same institution to determine if patient population characteristics, treatment approaches, and clinical outcomes had undergone change over the two study periods. Materials and Methods: Data from a prospective soft tissue tumor database was used to analyze clinical courses of 189 desmoid patients treated at The University of Texas M.D. Anderson Cancer Center (UTMDACC) from 1995 to 2005 as compared with 189 UTMDACC desmoid patients treated between 1965 and 1994. Results: A nearly three-fold increase in annualized UTMDACC desmoid referral volume with significantly higher percentages and numbers of primary desmoid tumor referrals to UTMDACC was observed in the most recent study period. Significantly increased systemic therapy use and decreased reliance on surgery alone was observed more recently. While the recent series patients had higher rates of macroscopic residual disease and equivalent rates of positive microscopic margins after definitive surgery, the estimated 5-year local recurrence rate of 20{\%} was improved compared with the 30{\%} rate observed in the earlier series. Conclusion: Increased awareness of the complex multidisciplinary management needed for desmoid tumor control may underlie significantly increased numbers of referrals to UTMDACC, especially primary untreated desmoids. Increased neoadjuvant treatments may be associated with improved desmoid patient outcomes. These trends should be supported, particularly if personalized molecular-based therapies are to be rapidly and effectively deployed for the benefit of those afflicted by this rare and potentially debilitating disease.",
author = "Dina Lev and Dhanasekaran Kotilingam and Caimiao Wei and Matthew Ballo and Zagars, {Gunar K.} and Pisters, {Peter W T} and Lazar, {Alexander A.} and Patel, {Shreyaskumar R.} and Benjamin, {Robert S.} and Pollock, {Raphael E.}",
year = "2007",
month = "5",
day = "1",
doi = "10.1200/JCO.2006.10.5015",
language = "English (US)",
volume = "25",
pages = "1785--1791",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "13",

}

TY - JOUR

T1 - Optimizing treatment of desmoid tumors

AU - Lev, Dina

AU - Kotilingam, Dhanasekaran

AU - Wei, Caimiao

AU - Ballo, Matthew

AU - Zagars, Gunar K.

AU - Pisters, Peter W T

AU - Lazar, Alexander A.

AU - Patel, Shreyaskumar R.

AU - Benjamin, Robert S.

AU - Pollock, Raphael E.

PY - 2007/5/1

Y1 - 2007/5/1

N2 - Purpose: This study compared a large series of desmoid patients treated at a single institution to a previously published series from the same institution to determine if patient population characteristics, treatment approaches, and clinical outcomes had undergone change over the two study periods. Materials and Methods: Data from a prospective soft tissue tumor database was used to analyze clinical courses of 189 desmoid patients treated at The University of Texas M.D. Anderson Cancer Center (UTMDACC) from 1995 to 2005 as compared with 189 UTMDACC desmoid patients treated between 1965 and 1994. Results: A nearly three-fold increase in annualized UTMDACC desmoid referral volume with significantly higher percentages and numbers of primary desmoid tumor referrals to UTMDACC was observed in the most recent study period. Significantly increased systemic therapy use and decreased reliance on surgery alone was observed more recently. While the recent series patients had higher rates of macroscopic residual disease and equivalent rates of positive microscopic margins after definitive surgery, the estimated 5-year local recurrence rate of 20% was improved compared with the 30% rate observed in the earlier series. Conclusion: Increased awareness of the complex multidisciplinary management needed for desmoid tumor control may underlie significantly increased numbers of referrals to UTMDACC, especially primary untreated desmoids. Increased neoadjuvant treatments may be associated with improved desmoid patient outcomes. These trends should be supported, particularly if personalized molecular-based therapies are to be rapidly and effectively deployed for the benefit of those afflicted by this rare and potentially debilitating disease.

AB - Purpose: This study compared a large series of desmoid patients treated at a single institution to a previously published series from the same institution to determine if patient population characteristics, treatment approaches, and clinical outcomes had undergone change over the two study periods. Materials and Methods: Data from a prospective soft tissue tumor database was used to analyze clinical courses of 189 desmoid patients treated at The University of Texas M.D. Anderson Cancer Center (UTMDACC) from 1995 to 2005 as compared with 189 UTMDACC desmoid patients treated between 1965 and 1994. Results: A nearly three-fold increase in annualized UTMDACC desmoid referral volume with significantly higher percentages and numbers of primary desmoid tumor referrals to UTMDACC was observed in the most recent study period. Significantly increased systemic therapy use and decreased reliance on surgery alone was observed more recently. While the recent series patients had higher rates of macroscopic residual disease and equivalent rates of positive microscopic margins after definitive surgery, the estimated 5-year local recurrence rate of 20% was improved compared with the 30% rate observed in the earlier series. Conclusion: Increased awareness of the complex multidisciplinary management needed for desmoid tumor control may underlie significantly increased numbers of referrals to UTMDACC, especially primary untreated desmoids. Increased neoadjuvant treatments may be associated with improved desmoid patient outcomes. These trends should be supported, particularly if personalized molecular-based therapies are to be rapidly and effectively deployed for the benefit of those afflicted by this rare and potentially debilitating disease.

UR - http://www.scopus.com/inward/record.url?scp=34249046990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249046990&partnerID=8YFLogxK

U2 - 10.1200/JCO.2006.10.5015

DO - 10.1200/JCO.2006.10.5015

M3 - Article

VL - 25

SP - 1785

EP - 1791

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 13

ER -